Investigational drug · Phase 3
Mocertatug rezetecan
Also called: Mo-Rez
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ovarian Neoplasms, Neoplasms, Endometrial, Tumours, Gynecological.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
7
Any phase or sponsor naming "Mocertatug rezetecan"
First trial start
2025
Mar 4, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Mocertatug rezetecan", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ovarian Neoplasms
- Neoplasms, Endometrial
- Tumours, Gynecological
Approved drugs for the same conditions: Endometrial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Mocertatug rezetecan" as an intervention, largest first.
- Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07694427 · 720 participants (planned) · Start Oct 2, 2026 · Primary completion Sep 6, 2029
Drug: Mocertatug rezetecan; Bevacizumab · For: Ovarian Neoplasms
Sites: Buenos Aires, Argentina; CABA, Argentina; Ciudad Autonoma de Buenos Aire, Argentina · 12 sites in all
- A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07684612 · 690 participants (planned) · Start Sep 8, 2026 · Primary completion May 21, 2030
Drug: Mocertatug rezetecan (Mo-Rez); Carboplatin and 4 more · For: Ovarian Neoplasms
Sites: Newcastle, Australia; Toronto, Canada; Montreal, Canada · 9 sites in all
- A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT06431594 · 675 participants (planned) · Start Jul 2, 2024 · Primary completion Sep 22, 2027
Drug: Mocertatug rezetecan · For: Solid Tumors; Neoplasms
Sites: Birmingham, Alabama; Fountain Valley, California; Santa Rosa, California · 65 sites in all
- A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07684599 · 610 participants (planned) · Start Sep 24, 2026 · Primary completion Jul 23, 2029
Drug: Mocertatug rezetecan; Dostarlimab and 1 more · For: Neoplasms, Endometrial
Sites: Toronto, Canada; Montreal, Canada; Fukuoka, Japan · 12 sites in all
- A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07286331 · 600 participants (planned) · Start Jun 4, 2026 · Primary completion Feb 29, 2028
Drug: Mocertatug rezetecan; Paclitaxel and 1 more · For: Neoplasms, Endometrial
Sites: Birmingham, Alabama; Omaha, Nebraska; Sugar Land, Texas · 56 sites in all
- A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07286266 · 450 participants (planned) · Start Jun 18, 2026 · Primary completion Jul 22, 2030
Drug: Mocertatug rezetecan; Paclitaxel and 5 more · For: Ovarian Neoplasms
Sites: Randwick, Australia; Auchenflower, Australia; Toronto, Canada · 22 sites in all
- A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT06796907 · 305 participants (planned) · Start Mar 4, 2025 · Primary completion Jun 21, 2027
Drug: Mo-Rez; Dostarlimab and 1 more · For: Tumours, Gynecological
Sites: La Jolla, California; Aurora, Colorado; Rochester, New York · 83 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- BEHOLD phase 3 clinical development program of mocertatug rezetecan in ovarian and endometrial cancer.
Hurteau J, Grayeski M, Dixon J · Gynecol Oncol 2026
- BEHOLD-1 and -2: phase 1/2 randomized studies evaluating the B7 homolog 4 protein-targeted antibody-drug conjugate mocertatug rezetecan in patients with solid tumors, including endometrial and ovarian cancers.
Lheureux S, Provencher D, Baka S, et al. · Int J Gynecol Cancer 2026
Also in development for Ovarian Neoplasms
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- AL58805Phase 22 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- BMX-001Phase 21 trial
BioMimetix JV, LLC · Ovarian Neoplasms, Endometrial Cancer, Endometrial Neoplasm
- DM002Phase 21 trial
Xadcera Biopharmaceutical (Suzhou) Co., Ltd. · Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms
- VB15010Phase 21 trial
Zhejiang Yangli Pharmaceutical Technology Co., Ltd. · Cancer, Neoplasms, Neoplasms, Breast
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.